Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
More News: Abatacept | Academia | Actemra | Arthritis | Enbrel | Hydroxychloroquine | Methotrexate | Orencia | Remicade | Rheumatoid Arthritis | Rheumatology | Rituxan | Scleroderma